Chronic Fatigue Syndrome disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

Sources

Aliases & Classifications for Chronic Fatigue Syndrome

MalaCards integrated aliases for Chronic Fatigue Syndrome:

Name: Chronic Fatigue Syndrome ¹¹ ⁷⁵ ⁵³ ⁴¹ ¹⁴ ¹⁶ ⁷¹ ³³

Postviral Fatigue Syndrome ¹¹ ³¹ ³³

Myalgic Encephalomyelitis ¹¹ ⁷⁵ ³³

Cfs ¹¹ ¹⁴

Pvfs - [postviral Fatigue Syndrome] ³³

Myalgic Encephalomyelitis Syndrome ³³

Benign Myalgic Encephalomyelitis ³³

Cfs - [chronic Fatigue Syndrome] ³³

Me - [myalgic Encephalomyelitis] ³³

Encephalomyelitis, Myalgic ⁷⁵

Fatigue Syndrome, Chronic ⁴³

Epidemic Neuromyasthenia ³³

Myalgic Encephalitis ¹¹

Icelandic Disease ³³

Akureyri Disease ³³

Chronic Fatigue ⁵

Neuromyasthenia ³³

Iceland Disease ³³

Akureyri ³³

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases Mental diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Diseases of the nervous system

Other disorders of the nervous system

Other disorders of brain

Postviral fatigue syndrome

ICD11: ³³

Diseases of the nervous system

Other disorders of the nervous system

Postviral fatigue syndrome

External Ids:

Disease Ontology ¹¹ DOID:8544

ICD9CM ³⁴ 780.71

MeSH ⁴³ D015673

NCIt ⁴⁹ C3037

SNOMED-CT ⁶⁸ 193054000

ICD10 ³¹ G93.3

EFO ¹⁶ EFO_0004540

ICD11 ³³ 569175314

UMLS ⁷¹ C0015674

Sources

Summaries for Chronic Fatigue Syndrome

MedlinePlus: ⁴¹ What is chronic fatigue syndrome (CFS)? Chronic fatigue syndrome (CFS) is a serious, long-term illness that affects many body systems. Another name for it is myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). CFS can often make you unable to do your usual activities. Sometimes you may not even be able to get out of bed. What causes chronic fatigue syndrome (CFS)? The cause of CFS is unknown. There may be more than one thing that causes it. It is possible that two or more triggers might work together to cause the illness. Who is at risk for chronic fatigue syndrome (CFS)? Anyone can get CFS, but it is most common in people between 40 and 60 years old. Adult women have it more often that adult men. Whites are more likely than other races to get a diagnosis of CFS, but many people with CFS have not been diagnosed with it. What are the symptoms of chronic fatigue syndrome (CFS)? CFS symptoms can include: Severe fatigue that is not improved by rest Sleep problems Post-exertional malaise (PEM), where your symptoms get worse after any physical or mental activity Problems with thinking and concentrating Pain Dizziness CFS can be unpredictable. Your symptoms may come and go. They may change over time - sometimes they might get better, and other times they may get worse. How is chronic fatigue syndrome (CFS) diagnosed? CFS can be difficult to diagnose. There is no specific test for CFS, and other illnesses can cause similar symptoms. Your health care provider has to rule out other diseases before making a diagnosis of CFS. He or she will do a thorough medical exam, including: Asking about your medical history and your family's medical history Asking about your current illness, including your symptoms. Your doctor will want to know how often you have symptoms, how bad they are, how long they have lasted, and how they affect your life. A thorough physical and mental status exam Blood, urine, or other tests What are the treatments for chronic fatigue syndrome (CFS)? There is no cure or approved treatment for CFS, but you may be able to treat or manage some of your symptoms. You, your family, and your health care provider should work together to decide on a plan. You should figure out which symptom causes the most problems and try to treat that first. For example, if sleep problems affect you the most, you might first try using good sleep habits. If those do not help, you may need to take medicines or see a sleep specialist. Strategies such as learning new ways to manage activity can also be helpful. You need to make sure that you do not "push and crash." This can happen when you feel better, do too much, and then get worse again. Since the process of developing a treatment plan and attending to self-care can be hard if you have CFS, it is important to have support from family members and friends. Don't try any new treatments without talking to your health care provider. Some treatments that are promoted as cures for CFS are unproven, often costly, and could be dangerous. Centers for Disease Control and Prevention

MalaCards based summary: Chronic Fatigue Syndrome, also known as postviral fatigue syndrome, is related to irritable bowel syndrome and fibromyalgia, and has symptoms including muscle weakness, fatigue and fever. An important gene associated with Chronic Fatigue Syndrome is RNASEL (Ribonuclease L), and among its related pathways/superpathways are Signal Transduction and TGF-Beta Pathway. The drugs Ethanol and Sodium citrate have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and breast, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Disease Ontology: ¹¹ A syndrome that involves prolonged and severe tiredness or weariness that is unrelated to exertion, is not relieved by rest and for a minimum of six months and is not directly caused by other conditions.

Wikipedia: ⁷⁵ Chronic fatigue syndrome (CFS), also called myalgic encephalomyelitis (ME) or ME/CFS, is a complex,... more...

Sources

Related Diseases for Chronic Fatigue Syndrome

Diseases related to Chronic Fatigue Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 833)

#	Related Disease	Score	Top Affiliating Genes
1	irritable bowel syndrome	32.1	VIP SLC6A4 POMC IL6 HTR1A CRH
2	fibromyalgia	31.9	SLC6A4 POMC MAOA INS IL6 IGF1
3	viral infectious disease	31.6	RNASEL IL6 IL2 IFNG EIF2AK2
4	personality disorder	31.4	SLC6A4 NR3C1 MAOA HTR1A CRH
5	sleep disorder	31.4	SLC6A4 POMC INS IL6 IGF1 HTR1A
6	autoimmune disease	31.3	MIR146A INS IL6 IL2 IFNG
7	somatization disorder	31.2	SLC6A4 POMC IL6 CRH
8	premature ovarian failure 7	31.2	POMC GH1 CRH
9	apnea, obstructive sleep	31.2	POMC INS IL6 IGF1
10	paine syndrome	31.1	SLC6A4 POMC IL6 CRH
11	mood disorder	31.1	SLC6A4 POMC NR3C1 MAOA IL6 HTR1A
12	major depressive disorder	31.1	SLC6A4 POMC NR3C1 MAOA INS IL6
13	sleep apnea	31.0	SLC6A4 INS IL6 IGF1
14	anxiety	31.0	SLC6A4 POMC NR3C1 MAOA INS IL6
15	poliomyelitis	31.0	IL6 IL2 IFNG
16	acute stress disorder	30.9	SLC6A4 POMC NR3C1 CRH
17	chickenpox	30.9	IL6 IL2 IFNG
18	generalized anxiety disorder	30.9	SLC6A4 POMC MAOA IL6 HTR1A CRH
19	leptin deficiency or dysfunction	30.9	POMC INS IL6 IGF1 CRH
20	panic disorder	30.9	SLC6A4 POMC MAOA IL6 HTR1A CRH
21	rhinitis	30.9	VIP POMC NR3C1 IL6 IFNG
22	neurotic disorder	30.8	SLC6A4 POMC MAOA INS IL6 HTR1A
23	somatoform disorder	30.8	SLC6A4 POMC IL6 HTR1A CRH
24	hypochondriasis	30.8	SLC6A4 POMC MAOA HTR1A
25	dysthymic disorder	30.8	SLC6A4 POMC MAOA INS IL6 HTR1A
26	endogenous depression	30.8	SLC6A4 POMC NR3C1 MAOA INS IL6
27	celiac disease 1	30.8	INS IL6 IL2 IGF1 IFNG
28	post-traumatic stress disorder	30.7	SLC6A4 POMC NR3C1 MAOA IL6 HTR1A
29	amenorrhea	30.7	POMC INS IGF1 CRH
30	immune deficiency disease	30.7	RNASEL MIR146A INS IL6 IL2 IFNG
31	hypothyroidism	30.7	POMC INS IL2 IGF1 GH1
32	hypoglycemia	30.7	POMC NR3C1 INS IGFBP1 IGF2 IGF1
33	insulin-like growth factor i	30.7	INS IL6 IGFBP1 IGF2 IGF1 GH1
34	brucellosis	30.7	IL6 IL2 IFNG
35	thyroiditis	30.7	INS IL6 IL2 IFNG
36	connective tissue disease	30.7	MIR146A INS IL6 IL2 IGF1 IFNG
37	severe acute respiratory syndrome	30.7	IL6 IL2 IFNG
38	erythema multiforme	30.6	IL6 IL2 IFNG
39	persian gulf syndrome	30.6	VIP ADCYAP1
40	deficiency anemia	30.6	INS IL6 IL2 IGF1 GH1
41	exanthem	30.6	IL6 IL2 IFNG
42	rheumatoid arthritis	30.6	NR3C1 MIR146A IL6 IL2 IFNG CRH
43	primary biliary cholangitis	30.6	SUN2 INS IL6 IL2
44	agoraphobia	30.6	SLC6A4 MAOA HTR1A CRH
45	migraine with or without aura 1	30.5	VIP SLC6A4 POMC MAOA INS IL6
46	stomatitis	30.5	IL6 IL2 IFNG EIF2AK2
47	proteasome-associated autoinflammatory syndrome 1	30.5	INS IL6 IFNG
48	eating disorder	30.5	SLC6A4 POMC INS IGF1 HTR1A CRH
49	hypokalemia	30.5	VIP POMC NR3C1 INS CRH
50	psychotic disorder	30.5	SLC6A4 MIR146A MAOA INS IL6 HTR1A

Graphical network of the top 20 diseases related to Chronic Fatigue Syndrome:

Sources

Symptoms & Phenotypes for Chronic Fatigue Syndrome

UMLS symptoms related to Chronic Fatigue Syndrome:

muscle weakness; fatigue; fever; back pain; myalgia; pruritus; sciatica; muscle cramp; muscle rigidity; muscle spasticity; (non-specific) malaise and fatigue; other malaise and fatigue

GenomeRNAi Phenotypes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Reduced mammosphere formation	GR00396-S	9.17	ADCYAP1 EIF2AK2 IGF1 IGF2 MAOA NR3C1

MGI Mouse Phenotypes related to Chronic Fatigue Syndrome:

⁴⁵ (show all 19)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.46	ADCYAP1 CRH EIF2AK2 GH1 HTR1A IFNG
2	nervous system	MP:0003631	10.41	ADCYAP1 CRH GH1 HTR1A IFNG IGF1
3	growth/size/body region	MP:0005378	10.37	ADCYAP1 CRH EIF2AK2 GH1 IFNG IGF1
4	cellular	MP:0005384	10.33	ADCYAP1 CRH EIF2AK2 IFNG IGF1 IGF2
5	immune system	MP:0005387	10.3	ADCYAP1 CRH EIF2AK2 GH1 IFNG IGF1
6	endocrine/exocrine gland	MP:0005379	10.29	CRH GH1 IFNG IGF1 IGF2 IL2
7	liver/biliary system	MP:0005370	10.28	ADCYAP1 CRH GH1 IFNG IGF2 IGFBP1
8	behavior/neurological	MP:0005386	10.28	ADCYAP1 CRH GH1 HTR1A IFNG IGF2
9	no phenotypic analysis	MP:0003012	10.27	ADCYAP1 CRH HTR1A IFNG IGF2 IL2
10	cardiovascular system	MP:0005385	10.25	GH1 HTR1A IFNG IGF1 IGF2 IL2
11	renal/urinary system	MP:0005367	10.21	CRH GH1 IFNG IGF1 IGF2 IL6
12	muscle	MP:0005369	10.2	ADCYAP1 IFNG IGF1 IGF2 IL6 INS
13	neoplasm	MP:0002006	10.13	EIF2AK2 IFNG IGF1 IL2 IL6 MIR146A
14	adipose tissue	MP:0005375	10.13	ADCYAP1 CRH GH1 IGF1 IL6 INS
15	hematopoietic system	MP:0005397	10.03	ADCYAP1 CRH EIF2AK2 GH1 IFNG IGF1
16	reproductive system	MP:0005389	10	ADCYAP1 GH1 IFNG IGF1 IGF2 IL2
17	respiratory system	MP:0005388	9.97	CRH GH1 IFNG IGF1 IGF2 IL2
18	mortality/aging	MP:0010768	9.89	ADCYAP1 EIF2AK2 GH1 HTR1A IFNG IGF1
19	integument	MP:0010771	9.32	CRH IFNG IGF1 IGF2 IL6 INS

Sources

Drugs & Therapeutics for Chronic Fatigue Syndrome

Drugs for Chronic Fatigue Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Ethanol

Approved

Phase 4

64-17-5

702

2

Sodium citrate

Approved, Investigational

Phase 4

68-04-2

23431961

3

Sildenafil

Approved, Investigational

Phase 4

139755-83-2, 171599-83-0

5212 135398744

4

Doxycycline

Approved, Investigational, Vet_approved

Phase 4

564-25-0

54671203

5

Tetracycline

Approved, Vet_approved, Withdrawn

Phase 4

60-54-8

5353990

6

Sodium oxybate

Approved

Phase 4

502-85-2

23663870

7

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

8

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

9

Garlic

Approved, Nutraceutical

Phase 4

8008-99-9

10

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 4

77-92-9

311

11

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 4

59-30-3

6037

12

Thiamine

Approved, Investigational, Nutraceutical, Vet_approved

Phase 4

70-16-6

1130

13

Antioxidants

Phase 4

14

Protective Agents

Phase 4

15

Ginkgo

Phase 4

16

Allyl sulfide

Phase 4

17

Lemon Balm

Phase 4

18

Hawthorn

Phase 4

19

Diallyl Sulfide

Phase 4

20

Anti-Infective Agents

Phase 4

21

Central Nervous System Stimulants

Phase 4

22

Dopamine Uptake Inhibitors

Phase 4

23

Vasodilator Agents

Phase 4

24

Phosphodiesterase Inhibitors

Phase 4

25

Phosphodiesterase 5 Inhibitors

Phase 4

26

Citrate

Phase 4

27

Lisdexamfetamine Dimesylate

Phase 4

28

Liver Extracts

Phase 4

29

Anti-Bacterial Agents

Phase 4

30

Antiprotozoal Agents

Phase 4

31

Antiparasitic Agents

Phase 4

32

Antimalarials

Phase 4

33

Antibiotics, Antitubercular

Phase 4

34

Immunologic Factors

Phase 4

35

Immunosuppressive Agents

Phase 4

36

Complement System Proteins

Phase 4

37

Complement C1s

Phase 4

38

Complement C1 Inhibitor Protein

Phase 4

39

Complement C1 Inactivator Proteins

Phase 4

40

Vitamins

Phase 4

41

Folate

Phase 4

42

Vitamin B9

Phase 4

43

Trace Elements

Phase 4

44

Vitamin B Complex

Phase 4

45

Micronutrients

Phase 4

46

Vitamin B1

Phase 4

47

Thiamin

Phase 4

48

Anesthetics, Intravenous

Phase 4

49

Anesthetics, General

Phase 4

50

Anesthetics

Phase 4

Interventional clinical trials:

(show top 50) (show all 185)

#	Name	Status	NCT ID	Phase	Drugs
1	The Effect of Sodium Oxybate in Patients With Chronic Fatigue Syndrome.	Unknown status	NCT01584934	Phase 4	Sodium oxybate;Placebo
2	The Effect of Nasal CPAP in Patients With Chronic Fatigue and Sleep-disordered Breathing	Unknown status	NCT01368718	Phase 4
3	High-dose Ascorbic Acid Intravenous Injection Decreases Mitochondrial DNA Damage in Chronic Fatigue Patients: Randomized-controlled Study	Unknown status	NCT01926132	Phase 4	ascorbic acid 10g/20ml;Normal Saline 150ml
4	A Placebo-controlled, Randomized, Double-blind, Parallel, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of DA-5515 (Circulan® Soft Cap.) in Patients With Chronic Fatigue Symptoms Due to Impaired Blood Circulation	Unknown status	NCT03542721	Phase 4	DA-5515;Placebo of DA-5515
5	Chronic Fatigue Syndrome and Abdominal Symptoms After Giardia Infection: Clinical Evaluation, Biomarkers, Risk Factors and the Effect of Intervention	Completed	NCT00860236	Phase 4
6	Slow-wave Sleep and Daytime Functioning in Chronic Fatigue Syndrome: Effects of Sodium Oxybate	Completed	NCT02055898	Phase 4	Sodium Oxybate
7	Phase 4 Study of the Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With Chronic Fatigue Syndrome.	Completed	NCT00598585	Phase 4	Sildenafil (Viagra);Placebo
8	Use of Lisdexamfetamine Dimesylate in Treatment of Cognitive Impairment (Chronic Fatigue Syndrome): A Double Blind, Placebo Controlled Study	Completed	NCT01071044	Phase 4	Lisdexamfetamine Dimesylate;Placebo "30, 50 or 70 mg"
9	The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment	Completed	NCT01318356	Phase 4	Doxycycline;Placebo
10	A Randomized, Double Blind, Placebo Controlled, Cross-Over, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST (C1 Esterase Inhibitor [Recombinant]) in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection	Recruiting	NCT04705831	Phase 4	Ruconest
11	PBC Induced Fatigue Treated With Thiamine (PIFT) - The Effect of Oral Thiamine Supplement in 4 Weeks to Patients With Primary Biliary Cholangitis (PBC) and Chronic Fatigue. A Randomised Placebo Controlled Crossover Study	Recruiting	NCT04893993	Phase 4	Thiamine;Placebo
12	A Double-Blind, Randomized, Placebo-Controlled, Single-Center, Flexible Titration Study Evaluating the Efficacy of Solriamfetol in Treating Fatigue and Cognitive Symptoms in Adults Aged 18-65 Years With a Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome	Not yet recruiting	NCT04622293	Phase 4	Solriamfetol Oral Tablet [Sunosi];Placebo
13	Post-COVID-19 Chronic Fatigue Syndrome	Not yet recruiting	NCT05642923	Phase 4	Synthetic Vitamin B1
14	Phase IV - A Trial of Xyrem in the Treatment of Chronic Fatigue Syndrome.	Terminated	NCT00498485	Phase 4	Placebo;Sodium Oxybate
15	Clinical Trial, Randomized, Controlled, Parallel, to Evaluate the Effectiveness of Acupuncture as a Treatment in Patients Diagnosed With Chronic Fatigue Syndrome.	Unknown status	NCT01907711	Phase 2, Phase 3
16	A Randomized, Placebo-Controlled, Double-Blind Trial of Duloxetine in the Treatment of Patients With Chronic Fatigue Syndrome	Completed	NCT00375973	Phase 2, Phase 3	Duloxetine;Placebo
17	Cytokine Inhibition in Chronic Fatigue Syndrome Patients	Completed	NCT02108210	Phase 2, Phase 3	Anakinra;Placebo
18	B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-blind, Placebo-controlled Study.	Completed	NCT00848692	Phase 2, Phase 3	Rituximab;Saline (NaCl 0,9 %) (placebo)
19	A Multi-center, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Poly I:Poly C12U (Ampligen®) 400 mg IV Twice Weekly Versus Placebo in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME)	Completed	NCT00215800	Phase 3	Ampligen
20	B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Multicentre, Randomized, Double-blind and Placebo Controlled Phase-III Study With Rituximab Induction and Maintenance Treatment.	Completed	NCT02229942	Phase 3	Rituximab;Placebo
21	Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Clinical Study to Explore the Efficacy and Safety of GCJBP Laennec Inj.(Human Placenta Hydrolysate) 4ml Per Day 3 Times Per Week for 6 Weeks in the Chronic Fatigue Patients With Chronic Fatigue Syndrome or Idiopathic Chronic Fatigue	Completed	NCT01742013	Phase 3	GCJBP Laennec Inj.;Placebo
22	A Randomized, Double-blind, Placebo-controlled, Comparative Clinical Trial to Measure the Maximun Heart Rate During a Cycle Ergometer Test After ReConnect® Supplementation in CFS.	Completed	NCT02063126	Phase 2, Phase 3
23	Acupressure for Persistent Cancer-Related Fatigue in Breast Cancer Survivors	Completed	NCT01281904	Phase 2, Phase 3
24	A Randomized, Double-blind Placebo-controlled Phase III Trial of Coenzyme Q10 in Gulf War Illness	Completed	NCT02865460	Phase 3	Ubiquinol;Placebo
25	The Effect of ACTH (Acthar) on Measures of Chronic Fatigue in Patients With Relapsing Multiple Sclerosis.	Completed	NCT02315872	Phase 3	ACTH;Placebo
26	Adjunctive Treatment With Pramipexole for Anhedonic Depression Symptoms in Depression - PRIME-PRAXOL	Not yet recruiting	NCT05355337	Phase 3	Pramipexole;Placebo
27	Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Methylphenidate Hydrochloride as a Treatment for Chronic Fatigue Syndrome in Patients Taking a CFS-Specific Nutrient Formula	Unknown status	NCT01966276	Phase 2	Methyl-P plus Nutrient Formula;Methyl-P plus Nutrient matched placebos
28	Phase 1 + 2a Proof of Concept Study of Treatment of Chronic Fatigue Syndrome (CFS) With Iodinated Activated Charcoal (IodoCarb®)	Unknown status	NCT01793415	Phase 1, Phase 2	IodoCarb (r)
29	High-tech Acupuncture for Treatment of Chronic Fatigue Syndrome - A Sino-Austrian Cooperation Randomized Controlled Trial(RCT) on Heart Rate Variability	Unknown status	NCT02924831	Phase 2
30	Effects of Iron Therapy in Patients With Chronic Fatigue and IBD	Unknown status	NCT02517151	Phase 2	Ferric carboxymaltose;Placebo
31	The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome	Completed	NCT03674541	Phase 2	Pyridostigmine Bromide;Placebo
32	Behavioral Insomnia Therapy With Chronic Fatigue Syndrome	Completed	NCT00540254	Phase 1, Phase 2
33	A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Valganciclovir (Valcyte) in Patients Experiencing Chronic Fatigue Syndrome With Elevated Antibody Titers Against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV)	Completed	NCT00478465	Phase 1, Phase 2	valganciclovir
34	Pilot Phase 1/2, Open-Label, Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome	Completed	NCT03613129	Phase 1, Phase 2	CT38
35	Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS). Part A: an Open Label Phase-II Study With Six Intravenous Cyclophosphamide Infusions Four Weeks Apart, and Follow-up for 12 Months	Completed	NCT02444091	Phase 2	Cyclophosphamide
36	The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial	Completed	NCT01040429	Phase 2	Clonidine;Lactose capsula
37	Pacing Activity Self-management for Patients With Chronic Fatigue Syndrome: Randomized Controlled Clinical Trial	Completed	NCT01512342	Phase 2
38	B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. An Open Label Phase II Study With Rituximab Induction and Maintenance Treatment	Completed	NCT01156909	Phase 2	Rituximab
39	Mechanistic Assessment of N-Acetylcysteine as an Antioxidant Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Through Dose Response and Treatment Target Engagement	Recruiting	NCT04542161	Phase 2	NAC 900mg/day;NAC 3600mg/day;NAC 0mg/day (Placebo)
40	Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments	Recruiting	NCT03844412	Phase 2	5% lidocaine/5 mg/ml 0.02% estradiol compound cream;Nortriptyline;Placebo cream;Placebo pill
41	Improving Patient-Important Outcomes With Testosterone Replacement in Hypogonadal Men With a Prior History of Cancer	Recruiting	NCT04049331	Phase 2	Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]
42	Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?	Recruiting	NCT03983720	Phase 2
43	Fecal Microbiota Transplantation in Chronic Fatigue Syndrome - an RCT	Active, not recruiting	NCT03691987	Phase 2
44	A Double Blind Randomized Trial of Low-dose Naltrexone for Post-COVID Fatigue Syndrome	Not yet recruiting	NCT05430152	Phase 2	Low-Dose Naltrexone
45	Microbiome Targeted Oral Butyrate Therapy in Gulf War Multisymptom Illness	Not yet recruiting	NCT05367245	Phase 2	Cal-Mag Butyrate;Placebo
46	An Open-Label Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome	Terminated	NCT00977171	Phase 2	Droxidopa
47	Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Moderate and Serious Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis (CFS/ME), Including in Patients With no Clinical Response After B-lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab.	Terminated	NCT01730495	Phase 2	Etanercept
48	B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Severely Affected Chronic Fatigue Syndrome Patients. An Open Label Phase II Study With Rituximab Induction and Maintenance Treatment for Patients in WHO Performance Status III-IV	Terminated	NCT01156922	Phase 2	Rituximab
49	Chronic Fatigue Syndrome: Correction of Mitochondrial Dysfunction by Conditioning Exercise and Nutraceutical Therapy.	Withdrawn	NCT01471652	Phase 2	Nutraceutical supplements;Placebo
50	Autonomic Nervous System and Chronic Fatigue Syndrome	Completed	NCT00580619	Phase 1	L-NMMA trimethaphan;methyldopa

Search NIH Clinical Center for Chronic Fatigue Syndrome

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

coenzyme Q10

Fish Oils

venlafaxine

Venlafaxine hydrochloride

Cochrane evidence based reviews: fatigue syndrome, chronic

Sources

Genetic Tests for Chronic Fatigue Syndrome

Sources

Anatomical Context for Chronic Fatigue Syndrome

Organs/tissues related to Chronic Fatigue Syndrome:

MalaCards : Brain, Heart, Breast, Spinal Cord, Amygdala, Placenta, Endothelial

Sources

Publications for Chronic Fatigue Syndrome

Articles related to Chronic Fatigue Syndrome:

(show top 50) (show all 8244)

#	Title	Authors	PMID	Year
1	Tai Chi increases functional connectivity and decreases chronic fatigue syndrome: A pilot intervention study with machine learning and fMRI analysis. ⁶² ⁴¹	Wu K...Li K	36454926	2022
2	Measuring frailty and its association with key outcomes in the ambulance setting: a cross sectional observational study. ⁴¹	Charlton K...Stow D	36471316	2022
3	Development and assessment of an educational intervention to improve the recognition of frailty on an acute care respiratory ward. ⁴¹	Leblanc A...Mulpuru S	36454710	2022
4	Glucocorticoid receptor mediated negative feedback in chronic fatigue syndrome using the low dose (0.5 mg) dexamethasone suppression test. ⁵³ ⁶²	Papadopoulos A...Cleare AJ	18573538	2009
5	Combined dexamethasone/corticotropin-releasing factor test in chronic fatigue syndrome. ⁵³ ⁶²	Van Den Eede F...Claes SJ	17803834	2008
6	Unravelling intracellular immune dysfunctions in chronic fatigue syndrome: interactions between protein kinase R activity, RNase L cleavage and elastase activity, and their clinical relevance. ⁵³ ⁶²	Meeus M...De Meirleir K	18396793	2008
7	[Overlap between atypical depression, seasonal affective disorder and chronic fatigue syndrome]. ⁵³ ⁶²	Juruena MF...Cleare AJ	17546343	2007
8	Glucocorticoid receptor polymorphisms and haplotypes associated with chronic fatigue syndrome. ⁵³ ⁶²	Rajeevan MS...Reeves WC	16740143	2007
9	Inclusion of the glucocorticoid receptor in a hypothalamic pituitary adrenal axis model reveals bistability. ⁵³ ⁶²	Gupta S...Vernon SD	17300722	2007
10	Impairments of the 2-5A synthetase/RNase L pathway in chronic fatigue syndrome. ⁵³ ⁶²	Nijs J...De Meirleir K	16277015	2005
11	2',5'-Oligoadenylate size is critical to protect RNase L against proteolytic cleavage in chronic fatigue syndrome. ⁵³ ⁶²	Fremont M...Englebienne P	15924878	2005
12	Variability of the RNase L isoform ratio (37 kiloDaltons/83 kiloDaltons) in diagnosis of chronic fatigue syndrome. ⁵³ ⁶²	Tiev KP...Lebleu B	15699437	2005
13	Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635. ⁵³ ⁶²	Cleare AJ...Grasby PM	15691524	2005
14	Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. ⁵³ ⁶²	Gottschalk M...Weber F	15710856	2005
15	Do cytosine guanine dinucleotide (CpG) fragments induce vasoactive neuropeptide mediated fatigue-related autoimmune disorders? ⁵³ ⁶²	Staines DR	15922114	2005
16	Chronic ACTH autoantibodies are a significant pathological factor in the disruption of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome, anorexia nervosa and major depression. ⁵³ ⁶²	Wheatland R	15885924	2005
17	Reduction of serotonin transporters of patients with chronic fatigue syndrome. ⁵³ ⁶²	Yamamoto S...Watanabe Y	15570154	2004
18	Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome. ⁵³ ⁶²	Cleare AJ...Miell JP	15110921	2004
19	RNase L levels in peripheral blood mononuclear cells: 37-kilodalton/83-kilodalton isoform ratio is a potential test for chronic fatigue syndrome. ⁵³ ⁶²	Tiev KP...Cabane J	12626460	2003
20	Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. ⁵³ ⁶²	Tsigos C...Chrousos GP	12377295	2002
21	Ribonuclease L proteolysis in peripheral blood mononuclear cells of chronic fatigue syndrome patients. ⁵³ ⁶²	Demettre E...Lebleu B	12118002	2002
22	Antiviral pathway activation in patients with chronic fatigue syndrome and acute infection. ⁵³ ⁶²	Gow JW...Behan WM	11698994	2001
23	Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy. ⁵³ ⁶²	Cleare AJ...O'Keane V	11502777	2001
24	Increased sensitivity to glucocorticoids in peripheral blood mononuclear cells of chronic fatigue syndrome patients, without evidence for altered density or affinity of glucocorticoid receptors. ⁵³ ⁶²	Visser J...Nagelkerken L	11288761	2001
25	Abnormalities in response to vasopressin infusion in chronic fatigue syndrome. ⁵³ ⁶²	Altemus M...Straus SE	11087963	2001
26	A preliminary study of dehydroepiandrosterone response to low-dose ACTH in chronic fatigue syndrome and in healthy subjects. ⁵³ ⁶²	Scott LV...Dinan T	11104854	2000
27	A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. ⁵³ ⁶²	Hickie IB...Lloyd AR	11030484	2000
28	A 37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome. ⁵³ ⁶²	De Meirleir K...Lebleu B	11126321	2000
29	Desmopressin augments pituitary-adrenal responsivity to corticotropin-releasing hormone in subjects with chronic fatigue syndrome and in healthy volunteers. ⁵³ ⁶²	Scott LV...Dinan TG	10356627	1999
30	Blunted adrenocorticotropin and cortisol responses to corticotropin-releasing hormone stimulation in chronic fatigue syndrome. ⁵³ ⁶²	Scott LV...Dinan TG	9669518	1998
31	The low dose ACTH test in chronic fatigue syndrome and in health. ⁵³ ⁶²	Scott LV...Dinan TG	9713562	1998
32	A study of the immunology of the chronic fatigue syndrome: correlation of immunologic parameters to health dysfunction. ⁵³ ⁶²	Hassan IS...Bofill M	9576011	1998
33	Fibromyalgia, chronic fatigue syndrome, and myofascial pain. ⁵³ ⁶²	Bennett R	9567202	1998
34	Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome. ⁵³ ⁶²	Suhadolnik RJ...Pfleiderer W	9243369	1997
35	Changes in growth hormone, insulin, insulinlike growth factors (IGFs), and IGF-binding protein-1 in chronic fatigue syndrome. ⁵³ ⁶²	Allain TJ...Miell JP	9046989	1997
36	Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome. ⁵³ ⁶²	Suhadolnik RJ...Muller WE	7893988	1994
37	Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. ⁵³ ⁶²	Suhadolnik RJ...Carter WA	8148461	1994
38	The fragile process of Homecoming - Young women in recovery from severe ME/CFS. ⁶²	Krabbe SH...Mengshoel AM	36367977	2023
39	Subjective and objective cognitive function in adolescent with chronic fatigue following Epstein-Barr virus infection. ⁶²	Oie MG...Wyller VBB	36327530	2022
40	Can exercise training promote better sleep and reduced fatigue in people with chronic stroke? A systematic review. ⁶²	Tai D...Liu-Ambrose T	35762096	2022
41	Correction: Association between school absence and physical function in paediatric chronic fatigue syndrome/myalgic encephalopathy. ⁶²		36351760	2022
42	Response to the report published by the UK House of Commons All-Party Parliamentary Group on Chronic Fatigue Syndrome/Myalgic Encephalitis (CFS/ME): implications for cardiometabolic risk. ⁶²	Low S...Heald AH	36168429	2022
43	Severe myalgic encephalomyelitis/chronic fatigue syndrome in children and young people: a British Paediatric Surveillance Unit study. ⁶²	Royston AP...Crawley EM	36456114	2022
44	Brain fog of post-COVID-19 condition and Chronic Fatigue Syndrome, same medical disorder? ⁶²	Azcue N...Del Pino R	36474290	2022
45	Correction: Depression in paediatric chronic fatigue syndrome. ⁶²		36347570	2022
46	Assessing sleep and pain among adults with myalgic encephalomyelitis/chronic fatigue syndrome: psychometric evaluation of the PROMIS® sleep and pain short forms. ⁶²	Yang M...Lin JS	35896905	2022
47	The Impact of Micro RNA-320a Serum Level on Severity of Symptoms and Cerebral Processing of Pain in Patients with Fibromyalgia. ⁶²	Hussein M...Elanwar R	35587745	2022
48	Protracted stress-induced hypocortisolemia may account for the clinical and immune manifestations of Long COVID. ⁶²	Yavropoulou MP...Sfikakis PP	36182048	2022
49	Long Covid at the crossroads: Comparisons and lessons from the treatment of patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). ⁶²	Hunt J...Geraghty KJ	35341334	2022
50	Long COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome: Similarities and differences of two peas in a pod. ⁶²	Qanneta R	35693424	2022

Sources

Genes for Chronic Fatigue Syndrome

Genes related to Chronic Fatigue Syndrome (0 elite genes):

(show all 42)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	RNASEL	Ribonuclease L	Protein Coding	24.73	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7893988 8148461 15924878 (more) 16277015 11698994 12626460 15699437 11126321 18396793 9243369 12118002
2	POMC	Proopiomelanocortin	Protein Coding	19.67	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11104854 15885924 17546343 (more) 9713562 9669518 15710856
3	CRH	Corticotropin Releasing Hormone	Protein Coding	19.24	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11502777 10356627 15110921 (more) 12377295 9669518 11087963 17803834
4	NR3C1	Nuclear Receptor Subfamily 3 Group C Member 1	Protein Coding	17.7	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11288761 18573538 17300722 (more) 16740143
5	MAOA	Monoamine Oxidase A	Protein Coding	15.66	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11030484
6	EIF2AK2	Eukaryotic Translation Initiation Factor 2 Alpha Kinase 2	Protein Coding	15.38	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11698994 9243369
7	IL2	Interleukin 2	Protein Coding	14.01	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
8	IFNG	Interferon Gamma	Protein Coding	13.03	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	INS	Insulin	Protein Coding	12.76	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
10	IGF1	Insulin Like Growth Factor 1	Protein Coding	12.56	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	IGFBP1	Insulin Like Growth Factor Binding Protein 1	Protein Coding	12.4	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9046989
12	SUN2	Sad1 And UNC84 Domain Containing 2	Protein Coding	12.17	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9567202
13	GH1	Growth Hormone 1	Protein Coding	10.32	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	IGF2	Insulin Like Growth Factor 2	Protein Coding	10.24	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	ADCYAP1	Adenylate Cyclase Activating Polypeptide 1	Protein Coding	9.2	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15922114
16	VIP	Vasoactive Intestinal Peptide	Protein Coding	8.26	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15922114
17	SLC6A4	Solute Carrier Family 6 Member 4	Protein Coding	8.04	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15570154
18	HTR1A	5-Hydroxytryptamine Receptor 1A	Protein Coding	7.55	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15691524
19	MIR146A	MicroRNA 146a	RNA Gene	7.26	DISEASES inferred ¹⁴ ¹⁴
20	IL6	Interleukin 6	Protein Coding	7.1	DISEASES inferred ¹⁴
21	MIR126	MicroRNA 126	RNA Gene	7.09	DISEASES inferred ¹⁴ ¹⁴
22	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	6.96	DISEASES inferred ¹⁴ ¹⁴
23	MIR142	MicroRNA 142	RNA Gene	6.94	DISEASES inferred ¹⁴ ¹⁴
24	TNF	Tumor Necrosis Factor	Protein Coding	6.88	DISEASES inferred ¹⁴
25	SERPINA3	Serpin Family A Member 3	Protein Coding	6.84	DISEASES inferred ¹⁴ ¹⁴
26	IL1B	Interleukin 1 Beta	Protein Coding	6.76	DISEASES inferred ¹⁴
27	WWOX	WW Domain Containing Oxidoreductase	Protein Coding	6.76	DISEASES inferred ¹⁴
28	IL10	Interleukin 10	Protein Coding	6.71	DISEASES inferred ¹⁴
29	FHIT	Fragile Histidine Triad Diadenosine Triphosphatase	Protein Coding	6.65	DISEASES inferred ¹⁴
30	H2AC18	H2A Clustered Histone 18	Protein Coding	6.54	DISEASES inferred ¹⁴ ¹⁴
31	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	6.43	DISEASES inferred ¹⁴
32	CD4	CD4 Molecule	Protein Coding	6.42	DISEASES inferred ¹⁴
33	CRP	C-Reactive Protein	Protein Coding	6.39	DISEASES inferred ¹⁴
34	TRPM3	Transient Receptor Potential Cation Channel Subfamily M Member 3	Protein Coding	6.34	DISEASES inferred ¹⁴
35	POLD3	DNA Polymerase Delta 3, Accessory Subunit	Protein Coding	6.31	DISEASES inferred ¹⁴
36	CD8A	CD8a Molecule	Protein Coding	6.29	DISEASES inferred ¹⁴
37	MUS81	MUS81 Structure-Specific Endonuclease Subunit	Protein Coding	6.23	DISEASES inferred ¹⁴
38	IL4	Interleukin 4	Protein Coding	6.21	DISEASES inferred ¹⁴
39	XPR1	Xenotropic And Polytropic Retrovirus Receptor 1	Protein Coding	5.97	DISEASES inferred ¹⁴
40	BDNF	Brain Derived Neurotrophic Factor	Protein Coding	5.95	DISEASES inferred ¹⁴
41	FANCD2	FA Complementation Group D2	Protein Coding	5.92	DISEASES inferred ¹⁴
42	ASIC3	Acid Sensing Ion Channel Subunit 3	Protein Coding	5.88	DISEASES inferred ¹⁴

Sources

Variations for Chronic Fatigue Syndrome

ClinVar genetic disease variations for Chronic Fatigue Syndrome:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	MT-CO3	NC_012920.1:m.9355A>T	SNV	Uncertain Significance	523307	rs1556423663	GRCh37: MT:9355-9355 GRCh38: MT:9355-9355

Sources

Expression for Chronic Fatigue Syndrome

Search GEO for disease gene expression data for Chronic Fatigue Syndrome.

Sources

Pathways for Chronic Fatigue Syndrome

Pathways related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show all 42)

#	Super pathways	Score	Top Affiliating Genes
1	Signal Transduction ⁶⁶	13.61	ADCYAP1 CRH HTR1A IGF1 IGF2 IL2
2	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.49	INS IL6 IL2 IGF2 IGF1 IFNG
3	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.19	EIF2AK2 GH1 IFNG IL2 IL6 MAOA
4	p70S6K Signaling ⁶⁴ Show member pathways mTOR Pathway ⁶⁴ Renin-Angiotensin Pathway ⁶⁴	12.99	INS IL6 IL2 IGF2 IGF1 GH1
5	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.87	INS IL6 IL2 IGF2 IGF1 GH1
6	Nuclear receptors meta-pathway ⁷⁴ Show member pathways NRF2 pathway ⁷⁴	12.7	IFNG IGFBP1 IL2 NR3C1 SLC6A4
7	NF-KappaB Family Pathway ⁶⁴ Show member pathways NF-KappaB (p50-p65) Pathway ⁶⁴	12.57	IL6 IL2 IGF2 IGF1 GH1 EIF2AK2
8	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.42	RNASEL IL6 IL2 IGF2 IGF1 IFNG
9	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.34	IL6 IL2 IGF2 IGF1 GH1
10	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) ⁶⁶ Show member pathways Post-translational protein phosphorylation ⁶⁶	12.33	IGF1 IGF2 IGFBP1 IL6
11	Peptide hormone metabolism ⁶⁶ Show member pathways Glycoprotein hormones ⁶⁶ Metabolism of Angiotensinogen to Angiotensins ⁶⁶ Metabolism of Angiotensinogen to Angiotensins ⁷⁴ Peptide hormone biosynthesis ⁶⁶ Synthesis, secretion, and deacylation of Ghrelin ⁶⁶ thyroid hormone biosynthesis ⁶¹	12.14	POMC INS IGF1 GH1
12	G alpha (s) signalling events ⁶⁶ Show member pathways Defective ACTH causes obesity and POMCD ⁶⁶	12.1	VIP POMC CRH ADCYAP1
13	FOXO-mediated transcription ⁶⁶ Show member pathways FOXO-mediated transcription of cell cycle genes ⁶⁶ FOXO-mediated transcription of cell death genes ⁶⁶ FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes ⁶⁶ Regulation of FOXO transcriptional activity by acetylation ⁶⁶ Regulation of localization of FOXO transcription factors ⁶⁶	12.05	IGFBP1 INS NR3C1 POMC
14	Mesenchymal Stem Cells and Lineage-specific Markers ⁶⁵	11.84	INS IL6 IGF1
15	Corticotropin-releasing hormone signaling pathway ⁷⁴	11.82	POMC IL2 CRH
16	Adipogenesis ⁷⁴	11.77	NR3C1 INS IL6 IGF1 GH1
17	Acute viral myocarditis ⁷⁴	11.72	IL6 IL2 IFNG
18	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.71	IL6 IL2 IFNG
19	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.69	IL6 IL2 IFNG
20	Th17 cell differentiation pathway ⁷⁴	11.67	IL6 IL2 IFNG
21	G-protein signaling_RhoA regulation pathway ²²	11.66	IL6 IL2 IGF2 IGF1 GH1
22	Inflammatory bowel disease signaling ⁷⁴ Show member pathways Ulcerative colitis signaling ⁷⁴	11.58	IL6 IL2 IFNG
23	AP-1 transcription factor network ⁶¹	11.57	NR3C1 IL6 IL2 IFNG
24	Senescence and autophagy in cancer ⁷⁴	11.57	RNASEL INS IL6 IGF1 IFNG
25	ATF-2 transcription factor network ⁶¹	11.56	INS IL6 IFNG
26	SHP2 signaling ⁶¹	11.53	IL6 IL2 IFNG
27	Cardiac progenitor differentiation ⁷⁴	11.52	IGF1 IGF2 INS
28	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.5	NR3C1 IL6 IL2 IFNG
29	Pluripotent stem cell differentiation pathway ⁷⁴	11.46	INS IL6 IGF1
30	FOXA2 and FOXA3 transcription factor networks ⁶¹ Show member pathways FOXA transcription factor networks ⁶¹	11.4	NR3C1 INS IGFBP1
31	Sudden infant death syndrome (SIDS) susceptibility pathways ⁷⁴	11.3	SLC6A4 NR3C1 MAOA IL6 HTR1A ADCYAP1
32	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²²	11.28	IFNG IGF1 IL6 NR3C1
33	Glucocorticoid receptor regulatory network ⁶¹	11.24	POMC NR3C1 IL6 IL2 IFNG
34	Serotonin and anxiety ⁷⁴ Show member pathways Serotonin and anxiety-related events ⁷⁴	11.2	POMC HTR1A CRH
35	Cytokines and inflammatory response ⁷⁴	11.19	IL6 IL2 IFNG
36	Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics ⁶⁰	11.16	SLC6A4 MAOA HTR1A
37	Immune infiltration in pancreatic cancer ⁷⁴	11.13	IL6 IL2 IFNG
38	Methylphenidate Pathway, Pharmacodynamics ⁶⁰ Show member pathways Dopamine receptors ⁶⁶	11.03	SLC6A4 MAOA HTR1A
39	G-protein signaling_Rap2B regulation pathway ²²	10.98	IL6 IL2 IGF2 IGF1 GH1
40	RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) ⁶⁶	10.68	IL2 IFNG
41	COVID-19 adverse outcome pathway ⁷⁴	10.68	IL6 IL2
42	Glucocorticoid Pathway (HPA Axis), Pharmacodynamics ⁶⁰	10.49	POMC CRH

Sources

GO Terms for Chronic Fatigue Syndrome

Cellular components related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.98	POMC MIR146A INS IL6 IL2 IGFBP1
2	extracellular region	GO:0005576	9.7	ADCYAP1 CRH GH1 IFNG IGF1 IGF2

Biological processes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

(show all 13)

#	Name	GO ID	Score	Top Affiliating Genes
1	signal transduction	GO:0007165	10.37	POMC NR3C1 INS IL6 IGFBP1 IGF1
2	positive regulation of gene expression	GO:0010628	10.1	SLC6A4 MIR146A INS IL6 IGF1 IFNG
3	positive regulation of peptidyl-tyrosine phosphorylation	GO:0050731	10.01	IL6 IGF2 IGF1 GH1
4	positive regulation of chemokine production	GO:0032722	9.99	IL6 IFNG EIF2AK2
5	positive regulation of MAPK cascade	GO:0043410	9.96	INS IL6 IGF2 IGF1 EIF2AK2
6	positive regulation of glucose import	GO:0046326	9.95	IGF1 INS RNASEL
7	positive regulation of mitotic nuclear division	GO:0045840	9.93	INS IGF2 IGF1
8	positive regulation of activated T cell proliferation	GO:0042104	9.91	IL2 IGF2 IGF1
9	positive regulation of cell population proliferation	GO:0008284	9.86	VIP INS IL6 IL2 IGF2 IGF1
10	positive regulation of glycolytic process	GO:0045821	9.85	IFNG IGF1 INS
11	neuroinflammatory response	GO:0150076	9.7	NR3C1 IFNG
12	positive regulation of glycogen biosynthetic process	GO:0045725	9.63	IGF1 IGF2 INS
13	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	9.32	IL6 IL2 IGF1 IFNG GH1

Molecular functions related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	growth factor activity	GO:0008083	9.85	GH1 IGF1 IGF2 IL2 IL6
2	neuropeptide hormone activity	GO:0005184	9.8	VIP CRH ADCYAP1
3	insulin receptor binding	GO:0005158	9.73	INS IGF2 IGF1
4	hormone activity	GO:0005179	9.5	VIP POMC INS IGF2 IGF1 GH1
5	insulin-like growth factor receptor binding	GO:0005159	9.43	INS IGF2 IGF1

Sources

Sources for Chronic Fatigue Syndrome

¹ BitterDB

² CDC

³ Cell Signaling Technology

⁴ ClinicalTrials

⁵ ClinVar

⁶ CNVD

⁷ Cochrane Library

⁸ Cosmic

⁹ dbSNP

¹⁰ DGIdb

¹¹ Disease Ontology

¹² diseasecard

¹³ DiseaseEnhancer

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ EFO

¹⁷ ExPASy

¹⁸ FMA

¹⁹ GARD

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HMDB

³⁰ HPO

³¹ ICD10

³² ICD10 via Orphanet

³³ ICD11

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ LifeMap

³⁷ LncRNADisease

³⁸ LOVD

³⁹ MalaCards

⁴⁰ MedGen

⁴¹ MedlinePlus

⁴² MedlinePlus Genetics

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NINDS

⁵³ Novoseek

⁵⁴ Novus Biologicals

⁵⁵ ODiseA

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 08-Dec-2022)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubChem

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ WikiPathways

⁷⁵ Wikipedia

CFS MCID: CHR066 MIFTS: 58	Chronic Fatigue Syndrome (CFS) Categories: Mental diseases, Neuronal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Chronic Fatigue Syndrome (CFS)

Aliases & Classifications for Chronic Fatigue Syndrome

MalaCards integrated aliases for Chronic Fatigue Syndrome:

Classifications:

External Ids:

Summaries for Chronic Fatigue Syndrome

Related Diseases for Chronic Fatigue Syndrome

Diseases related to Chronic Fatigue Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Chronic Fatigue Syndrome:

Symptoms & Phenotypes for Chronic Fatigue Syndrome

UMLS symptoms related to Chronic Fatigue Syndrome:

GenomeRNAi Phenotypes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Chronic Fatigue Syndrome:

Drugs & Therapeutics for Chronic Fatigue Syndrome

Drugs for Chronic Fatigue Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Cochrane evidence based reviews: fatigue syndrome, chronic

Genetic Tests for Chronic Fatigue Syndrome

Anatomical Context for Chronic Fatigue Syndrome

Organs/tissues related to Chronic Fatigue Syndrome:

Publications for Chronic Fatigue Syndrome

Articles related to Chronic Fatigue Syndrome:

Genes for Chronic Fatigue Syndrome

Genes related to Chronic Fatigue Syndrome (0 elite genes):

Variations for Chronic Fatigue Syndrome

ClinVar genetic disease variations for Chronic Fatigue Syndrome:

Expression for Chronic Fatigue Syndrome

Pathways for Chronic Fatigue Syndrome

Pathways related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

GO Terms for Chronic Fatigue Syndrome

Cellular components related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

Biological processes related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

Molecular functions related to Chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

Sources for Chronic Fatigue Syndrome

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :